Down-regulation of FOS-like antigen 1 enhances drug sensitivity in breast cancer.
CONCLUSION: Down-regulation of FOSL1 potentiated chemotherapy sensitivity of breast cancer, and its lower expression attenuated chemotherapeutic drug resistance in human breast cancer cells. FOSL1 might be a drug target for predicting chemotherapy effect in breast cancer.
PMID: 32922605 [PubMed]
Source: International Journal of Clinical and Experimental Pathology - Category: Pathology Authors: Duan L, Zhao M, Ang L, Hu H, Wu Z, Wang J, Huang J, Zheng L, Dong W Tags: Int J Clin Exp Pathol Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Multidrug Resistance | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pathology | Study